<?xml version="1.0" encoding="UTF-8"?>
<p>The only drug approved at present for treatment of chronic hepatitis D is IFNα. In the largest multicenter trial, 61 Italian patients with chronic hepatitis D were randomly assigned to receive IFNα in doses of 5 MU/m
 <sup>2</sup> three times weekly for 4 months, followed by 3 MU/m
 <sup>2</sup> three times weekly for an additional 8 months or placebo [
 <xref ref-type="bibr" rid="CR122">122</xref>]. They were followed for another 12 months. Twenty-five percent of the 31 treated patients had normal serum transaminases versus none of the 30 controls at the end of the study. All but one of the responders had biochemical relapse after discontinuation of treatment.
</p>
